An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms (NCT05123365)

🧪 Interventions in This Study

• N-Acetylcysteine (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (2 Sites)

• University of California, Irvine — Irvine, California
• Chao Family Comprehensive Cancer Center, University of California, Irvine — Orange, California

📞 Contact the Study Coordinator

Phone: (714) 456-8000

Email: agf@hs.uci.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Myeloproliferative Neoplasm

• A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm — Duarte, California
• Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms — Buffalo, New York
• Evaluation of the Pathobiology of CALR-mutated MPN Cells — Charlotte, North Carolina
• Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms — Toronto, Ontario

Explore by condition: All Myeloproliferative Neoplasm clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.